Is cabotegravir approved?
TITUSVILLE, N.J., February 1, 2022 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced the U.S. Food and Drug Administration (FDA) has approved an expanded label for CABENUVA (rilpivirine and cabotegravir) to be administered every two months for the treatment of HIV-1 in virologically suppressed …
How does cabotegravir and rilpivirine work?
These medications work by decreasing the amount of HIV in the blood. Although cabotegravir and rilpivirine do not cure HIV, they may decrease your chance of developing acquired immunodeficiency syndrome (AIDS) and HIV-related illnesses such as serious infections or cancer.
How much does cabotegravir cost?
The manufacturer of cabotegravir (ViiV Healthcare) set the initial list price for the long-acting drug at $3700 per dose. Therefore, the required 2 doses in the first month and subsequent dosing every other month will cost $22 200 per year.
Who makes cabotegravir and rilpivirine?
ViiV HEALTHCARE ANNOUNCES US FDA APPROVAL OF CABENUVA (CABOTEGRAVIR, RILPIVIRINE) FOR USE EVERY TWO MONTHS, EXPANDING THE LABEL OF THE FIRST AND ONLY COMPLETE LONG-ACTING HIV TREATMENT.
What class is rilpivirine in?
Rilpivirine is in a class of medications called non-nucleoside reverse transcriptase inhibitors (NNRTIs). It works by decreasing the amount of HIV in the blood.
Who makes cabotegravir?
ViiV Healthcare announces US FDA approval of Apretude (cabotegravir extended-release injectable suspension), the first and only long-acting injectable option for HIV prevention | GSK. We are a science-led global healthcare company with a special purpose to improve the quality of human life.
What class is cabotegravir?
Cabotegravir is in a class of medications called HIV integrase inhibitors.
What is cabotegravir used for?
Cabotegravir is used along with rilpivirine (Edurant) as a short-term treatment of human immunodeficiency virus type 1 (HIV-1) infection in certain adults. It is used to see if the body can tolerate cabotegravir before receiving the cabotegravir injection and in certain cases of missed doses of cabotegravir injection.
When was rilpivirine FDA approved?
Titusville, NJ, May 20, 2011 – The US Food and Drug Administration (FDA) today approved EDURANTTM (rilpivirine) tablets for use in combination with other antiretroviral agents (ARVs) in the treatment of human immunodeficiency virus type 1 (HIV-1) in adults who have never taken HIV therapy (treatment‑naïve).
Who is cabotegravir?
Cabotegravir is an antiretroviral drug (ARV) developed by ViiV Healthcare and formulated as an injectable, administered every two months, for PrEP. It is an integrase inhibitor, the same class of drugs that includes the widely-used treatment drug dolutegravir.
What is the difference between rilpivirine and cabotegravir?
Cabotegravir and rilpivirine are medications used to treat HIV, delivered by injection. They have been engineered to stay in the body after injection for at least two months. In Europe, long-acting cabotegravir is marketed under the name Vocabria. Long-acting rilpivirine is marketed under the name Rekambys.
How long does long-acting cabotegravir stay in the body?
They have been engineered to stay in the body after injection for at least two months. In Europe, long-acting cabotegravir is marketed under the name Vocabria.
What class of drug is cabotegravir?
Cabotegravir is from a class of drugs known as integrase inhibitors. Each drug class works against HIV in a different way. The aim of HIV treatment is to reduce the level of HIV in your body (viral load). Ideally, your viral load should become so low that it is undetectable – usually less than 50 copies of virus per ml of blood.
What is the generic name for long acting rilpivirine?
Long-acting rilpivirine is marketed under the name Rekambys. The two injectable treatments must be given together and not combined with other HIV medicines.